nivolumab,ipilimumab
bms
['niche-2']
at #esmo22: impressive results from the niche-2 trial may open a way to a watch and wait approach for patients with #dmmr #coloncancer 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.